DavidMichaelSwobodaMD

PubMed

• Validation of Molecular International Prognostic Scoring System (IPSS-M) in myelodysplastic/myeloproliferative neoplasms, not otherwise specified (MDS/MPN-NOS).
  Abhishek A Mangaonkar, David M Swoboda, Terra L Lasho, Christy Finke, Rhett P Ketterling, Kaaren K Reichard, Rami Komrokji, Eric Padron, Mrinal M Patnaik> ;Leukemia Research. 2023 Aug 1
• 3 citations
  Hypomethylating agent and venetoclax in patients with chronic myelomonocytic leukemia: Is the combination indeed better?
  Somedeb Ball, Akriti G Jain, Najla Al Ali, Yumeng Zhang, Onyee Chan, Andrew T Kuykendall, Kendra L Sweet, Jeffrey E Lancet, David M Swoboda, Eric Padron, Rami S Komrok...> ;American Journal of Hematology. 2022 May 1
• 5 citations
  Marrow ring sideroblasts are highly predictive for TP53 mutation in MDS with excess blasts.
  David M Swoboda, Rashmi Kanagal-Shamanna, Andrew M Brunner, Thomas Cluzeau, Onyee Chan, Najla Al Ali, Guillermo Montalban-Bravo, Quinto J Gesiotto, Alexander Gavralidi...> ;Leukemia. 2022 Apr 1
• 8 citations
  PET/CT scan and biopsy-driven approach for safe anti-PD-1 therapy discontinuation in patients with advanced melanoma.
  Geoffrey T. Gibney, Jacob Zaemes, Shelly Shand, Neil J. Shah, David M Swoboda, Kellie Gardner, Arash Radfar, Vesna Petronic-Rosic, Michael J. Reilly, Waddah B. Al-Refa...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
• 5 citations
  Leukocytosis is associated with end organ damage and mortality in chronic myelomonocytic leukemia and can be mitigated by cytoreductive therapy
  Anthony M. Hunter, Najla Al Ali, Anne Mai, Savan Shah, David M Swoboda, Andrew T. Kuykendall, Chetasi Talati, Kendra Sweet, David A. Sallman, Jeffrey E. Lancet, Rami S...> ;Leukemia Research. 2021 Jun 10
• 7 citations
  Validation of the international working group proposal for SF3B1 mutant myelodysplastic syndromes
  Rami S. Komrokji, Virginia O. Volpe, Onyee Chan, Najla Al Ali, David M Swoboda, Andrew T. Kuykendall, Eric Padron, David A. Sallman> ;Blood. 2021 Sep 16
• 5 citations
  Genomic stratification of myelodysplastic/myeloproliferative neoplasms, unclassifiable: Sorting through the unsorted
  Abhishek A. Mangaonkar, David M Swoboda, Terra L. Lasho, Christy Finke, Rhett P. Ketterling, Kaaren K. Reichard, Eric Padron, Chetasi Talati, Mrinal M. Patnaik> ;Leukemia. 2021 Apr 30
• 13 citations
  Genomic Characteristics and Prognostic Significance of Co-mutated ASXL1/SRSF2 Acute Myeloid Leukemia
  Daniel R. Richardson, David M Swoboda, Dominic T. Moore, Steven M Johnson, Onyee Chan, Jonathan Galeotti, Sonia Esparza, Mohammad Hussaini, Hendrick W. van Deventer, M...> ;American Journal of Hematology. 2021 Apr 1
• 4 citations
  Evaluating Predictors of Immune-Related Adverse Events and Response to Checkpoint Inhibitors in Myeloid Malignancies
  Quinto Gesiotto, David M Swoboda, Rory M. Shallis, Najla Al Ali, Eric Padron, Andrew T. Kuykendall, Jinming Song, Chetasi Talati, Kendra Sweet, Jeffrey E. Lancet, Amer...> ;Clinical Lymphoma, Myeloma & Leukemia. 2020 Nov 5
• 1 citations
  Challenges in the Evaluation and Management of Toxicities Arising From Immune Checkpoint Inhibitor Therapy for Patients With Myeloid Malignancies.
  Rory M. Shallis, Jan Philipp Bewersdorf, David M Swoboda, Wei Wei, Lohith Gowda, Thomas Prebet, Stephanie Halene, Manoj M. Pillai, Terri L. Parker, Natalia Neparidze, ...> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Jan 12
• 10 citations
  PTPN11 mutations are associated with poor outcomes across myeloid malignancies.
  David M Swoboda, Najla Al Ali, Onyee Chan, Eric Padron, Andrew T. Kuykendall, Jinming Song, Mohammad Hussaini, Chetasi Talati, Kendra Sweet, Jeffrey E. Lancet, David A...> ;Leukemia. 2021 Jan 1
• 17 citations
  The promise of macrophage directed checkpoint inhibitors in myeloid malignancies.
  David M Swoboda, David A. Sallman> ;Best Practice & Research. Clinical Haematology. 2020 Dec 1
• 1 citations
  Novel therapies in myelodysplastic syndromes.
  David M Swoboda, Quinto Gesiotto, David A. Sallman> ;Current Opinion in Hematology. 2020 Mar 1
• 31 citations
  Clinicopathologic characteristics, prognostication and treatment outcomes for myelodysplastic/myeloproliferative neoplasm, unclassifiable (MDS/MPN-U): Mayo Clinic-Moff...
  Abhishek A. Mangaonkar, David M Swoboda, Giacomo Coltro, Terra L. Lasho, Paul J. Novotny, Prateek Pophali, Ryan M. Carr, Moritz Binder, Christy Finke, Naseema Gangat, ...> ;Leukemia. 2020 Feb 1
• 2 citations
  Mutation-Driven Therapy in MDS
  David M Swoboda, David A. Sallman> ;Current Hematologic Malignancy Reports. 2019 Dec 1
• 3 citations
  Descriptive analysis of genetic aberrations and cell of origin in Richter transformation
  Ami Chitalia, David M Swoboda, Justine N. McCutcheon, Metin Ozdemirli, Nadia Khan, Bruce D. Cheson> ;Leukemia & Lymphoma. 2019 Jan 11
• 4 citations
  T315I-mutated myeloid sarcoma.
  Yumeng Zhang, David M. Swoboda, Aditya Grover, Lisa Nodzon, Ling Zhang, Javier Pinilla-Ibarz> ;Leukemia Research Reports. 2019 Jan 1
• Join now to see all

Journal Articles

• T315I-mutated myeloid sarcoma  
  Yumeng Zhang, David M. Swoboda, Aditya Grover, Lisa Nodzon, Ling Zhang, Javier Pinilla-Ibarz, Leukemia Research Reports, 8/17/2019

Abstracts/Posters

• OPB-111077 in Combination with Decitabine and Venetoclax for the Treatment of Acute Myeloid Leukemia
  David M Swoboda, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Lectures

• Marrow Ring Sideroblasts Are Highly Predictive for TP53 Mutation in MDS with Excess Blasts 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019